$EXPI Announces Appointment of Independent Director

$MKGI Appoints #SimonOrange to #BoardOfDirectors, Ramping Towards @NASDAQ Listing

Appointment Advances Monaker’s Plans for NASDAQ Listing

$CEMP to Present at $JPM #Healthcare #Conference

CHAPEL HILL, N.C., Jan. 04, 2017 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 35th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present at 3:30 p.m. PT (6:30 p.m. ET) on Wednesday, January 11, 2017 in San Francisco.

A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP). Cempra is currently seeking approval for both intravenous and oral capsule formulations from the FDA and the EMA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Fusidic acid is Cempra’s second product candidate, which has completed enrollment of an initial Phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI). Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

Company Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com

Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932
robert.uhl@westwicke.com

Media Contact:  
Melyssa Weible
Elixir Health PR
+1 201 723 5805
mweible@elixirhealthpr.com

$EFOI #LED lights Verified with “Less Than 1%” Flicker by #UL

First in the U.S. lighting industry with UL-verified flicker performance

SOLON, Ohio, Jan. 04, 2017  — Energy Focus, Inc. (NASDAQ:EFOI), a leader in LED lighting technologies, today announced its new 500D series tubular LED lighting products are the first in the U.S. verified as “Low Optical Flicker, Less Than 1%” by UL, a leading global safety science company for products including electrical devices and components. The designation confirms Energy Focus’ industry-leading status as an innovator of LED lighting technology and commitment to developing flicker-free lighting.

Optical flicker is any fluctuations in brightness over time.  Flicker of sufficiently low frequency can be visually perceived as blinking or flashing.  Higher frequency flicker is invisible to the human eye but puts stress on the human brain as it processes visuals, and is a known cause of headache and eyestrain.   People who have visual hypersensitivity, especially those on the autism spectrum, are susceptible to adverse reactions to fluctuations in light. People with photosensitive epilepsy may experience seizures from flickering light. While LEDs are capable of flicker-free lighting, flicker is often present as a result of low-quality drivers having output current ripple.  By engineering our driver to remove current ripple, Energy Focus products ensures practically flicker-free operation that avoids potential flicker-induced health risks.

UL Verification is an objective, science-based assessment that confirms the accuracy of marketing claims.  The flicker marketing claim Verification service was created in response to new requirements in California Title 24, a new standard designed to reduce commercial and residential energy consumption, for reduced-flicker lighting, as well as address market demand for third-party verified flicker results. This test measures all types of flicker, including frequencies of flicker higher than what the eye can “see” as flashing or blinking, but also the higher frequency, invisible flicker.

“Concern over the effects of optical flicker from lighting on occupants, particularly LED products, has been a frequent topic in the lighting industry,” said Austin Gelder, Technical Advisor for UL’s Lighting division. “The UL Verified Program for Optical Flicker was developed to analyze the optical waveform generated by the product in multiple frequency ranges against the IEEE 1789 recommended practice, and recognizes products that have placed significant effort into their design to minimize the flicker. These requirements are stringent, and the Energy Focus 500D series had less than 1/10^th of the maximum flicker allowed by the program.  It is great to see a lighting manufacturer addressing occupant comfort by prioritizing low flicker in their product design.”

IEEE, or Institute of Electrical and Electronic Engineers, is the world’s largest technical professional organization with a core purpose to foster technological innovations for the benefit of humanity. IEEE Recommended Practice #1789 sets a threshold for “no human impact” of 5% flicker at 120Hz. A new California law requires that flicker be less than 30% when measured at full brightness, and, for lamps that dim, at 20% brightness. UL’s results show less than 0.50% flicker on Energy Focus’ new 500D products.

To learn more about Energy Focus, please call 1-800-327-7877 or visit www.energyfocus.com.

About Energy Focus 
Energy Focus is an industry-leading innovator of energy-efficient LED lighting technology. As the creator of the only UL-verified low-flicker LED products on the market, Energy Focus products provide extensive energy savings, aesthetics, safety and health benefits over conventional and fluorescent lighting.

As a longstanding partner with the US Government providing energy efficient LED lighting products to the U.S. Navy and the Military Sealift Command fleets, Energy Focus products go through rigorous testing in the most adverse conditions possible and still have a zero percent failure rate. In the commercial sphere, customers include national, state and local U.S. government agencies as well as Fortune 500 companies across education, healthcare, retail and manufacturing. Energy Focus is headquartered in Solon, Ohio, with additional sales offices in Washington, D.C., New York and Taiwan.

Media Contact:
Michael Miller
Content Strategist
Energy Focus, Inc.
msmiller@energyfocusinc.com
(440) 715-1300 Office
(734) 945-6359 Cell

Investor Contact:
Peter Seltzberg
Darrow Associates, Inc.
pseltzberg@darrowir.com
(516) 419-9915

$INVE #Hirsch #FICAM Solution 2016 Winner #HomelandSecurity Awards

FREMONT, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) — Identiv, Inc.  (NASDAQ:INVE) today announced that its award-winning Hirsch government Federal Identity, Credential, and Access Management (FICAM) solution, developed to implement a simple, affordable FICAM-compliant solution simply with optimal performance, has been selected by Government Security News (GSN) as a winner in two categories of its Homeland Security Awards Program. Identiv was selected as the winner in the “Vendors of IT Security Products and Solutions” category as “Best Physical Logical Privileged Access Management Solution” and finalist as “Best User and Entity Behavior Analytics (UEBA) Solution”. Identiv was also selected as the winner in the “Vendors of Physical Security Products and Solutions” category as “Best Access Control Hardware”.

Now in its eighth year, the GSN Awards are recognized as the gold standard of accomplishments and the “best of the best” in IT and cybersecurity, physical security products and services, and the most notable government agency programs, initiatives, and innovations. GSN covers a broad range of homeland security topics including IT and cybersecurity, airport/seaport security, maritime security, law enforcement, video surveillance, law enforcement at federal state, local, and municipal, satellite communications, immigration and border security, critical infrastructure protection, and more.

“There were no inferior security products or services that I evaluated,” said Chuck Brooks, Lead Homeland Security Awards Judge. “They were all stellar. The approaches and methods sometimes differed among the entries, and that is largely because they were highly focused on their specific client needs. As to the government entries, these submissions exemplify the best in public/private cooperation. Government is moving rapidly into the digital era and integrating technologies, processes and accordingly new mandates of their government agencies and programs.”

“We are very pleased to name Hirsch by Identiv’s U.S. government FICAM solution as a winner in multiple categories of the GSN Homeland Security Awards,” said Adrian Courtenay, GSN CEO. “This year, the awards were more difficult than ever to judge because of the incredibly fast pace of change in the categories involved. Identiv was up against impressive competition.”

“Long known as the premier provider of access control and security management systems for government agencies and facilities, our Hirsch government team has applied their expertise built over the years to our Velocity-based FICAM-compliant solution,” said Steve Humphreys, Identiv CEO. “Any of the thousands of doors or portals our systems control in the government space can be easily upgraded to FICAM compliance without the cost and hassle of a forklift replacement, as we leverage virtually all of the existing Hirsch system infrastructure. Those sites needing to replace non-compliant systems will also find our solution extremely cost-effective and quick to deploy, as we don’t rely on third-party certificate processing hardware like so many others. Being recognized by GSN only further reinforces the need for a complete, secure, cost-effective solution for FICAM compliance.”

Identiv’s end-to-end FICAM solution has been developed to address an industry-wide problem of how to implement FICAM simply and with optimal performance. Until now, FICAM solutions from other vendors have been expensive, increasingly difficult to set up, and slow to provide authentication and access at the door. Identiv’s conceptual approach to FICAM and the Federal Information Processing Standard (FIPS) 201 Topology Categories addresses current PACS Infrastructure, Validation System, and Personal Identity Verification (PIV) Reader and is faster and less expensive than the competition. Learn more about Identiv’s solution by visiting identiv.com/ficam, requesting a meeting with an expert, or watching a video demo.

More information about Government Security News, the Homeland Security Awards Programs, and finalists and award winners of 2016 can be found at gsnmagazine.com.

About Identiv
Identiv, Inc. is the leading global player in physical security and secure identification. Identiv’s products, software, systems, and services address the markets for physical and logical access control and a wide range of RFID-enabled applications. Customers in the government, enterprise, consumer, education, healthcare, and transportation sectors rely on Identiv’s access and identification solutions. Identiv’s mission is to secure the connected physical world: from perimeter to desktop access, and from the world of physical things to the Internet of Everything. Identiv is a publicly traded company and its common stock is listed on the NASDAQ Capital Market in the U.S. under the symbol “INVE”. For more information, visit identiv.com.

Media Contact:
press@identiv.com

$EMAN to Demonstrate Their Highest Brightness #OLED Displays at #CES

eMagin Corporation, or the “Company” (NYSE MKT:EMAN), a leader in the development, design and manufacture of Active Matrix OLED microdisplays for high resolution imaging products, today announced that management will be demonstrating their highest brightness, direct patterned micro-displays designed for the virtual reality (VR) and augmented reality (AR) market by appointment to select customers at CES. eMagin is the only company that has designed and manufactured OLED microdisplays which provide the brightness that consumer products companies demand for their next generation VR and AR headsets.

“I am pleased to report we achieved what we set out to do at the beginning of 2016,” commented Andrew Sculley, President and CEO of eMagin. “We are shipping the 2K x 2K display as part of an agreement with a Tier One company that we entered into last year. We previously stated that we expected to sign at least one additional agreement with a Tier One partner in 2016. I am happy to announce that we met this goal and anticipate signing additional agreements in 2017. Our pipeline of interested parties continues to grow, including OEM partners and mass production partners, both of whom are important for commercializing and scaling production of our cutting-edge technology. We have developed and will be demonstrating full color OLED at brightness levels above 4,000 nits that can be mass produced to achieve truly immersive virtual reality.”

To learn more or schedule a demonstration, contact Steve Costello, VP of Business Development at scostello@emagin.com or 617-462-9726.

“Also, during the fourth quarter we launched our two consumer night vision products, the award-winning BlazeSpark smartphone attachment and the BlazeTorch goggles, both of which are being shown at CES. Overall, our efforts in 2016 laid the foundation for a strong 2017 as we further capitalize on our technology development and marketing initiatives,” concluded Mr. Sculley.

About eMagin Corporation

A leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how and mobile display systems, eMagin manufactures high-resolution OLED microdisplays and integrates them with magnifying optics to deliver virtual images comparable to large-screen computer and television displays in portable, low-power, lightweight personal displays. eMagin’s microdisplays provide near-eye imagery in a variety of products from military, industrial, medical and consumer OEMs. More information about eMagin is available at www.emagin.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding eMagin Corporation’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company’s most recent filings with the SEC. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. The business and operations of the Company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements

$OIIM Revises Fourth Quarter 2016 Financial Guidance

GEORGE TOWN, Grand Cayman, Jan. 04, 2017  — O2Micro® International Limited (NASDAQ:OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, today revised its guidance for the fourth quarter of 2016. The company now expects its fourth quarter revenue to be approximately $15.4 million to $15.9 million, an increase of the Company’s previous guidance of $14.7 million to $15.6 million. In addition, gross margin for the fourth quarter is expected to be between 53% and 55%, versus the Company’s previous guidance of 51% to 53%.  The increase in anticipated revenue for the fourth quarter is primarily the result of increased demand for High End TV and Power Tools.  Gross Margins benefitted from continued cost reductions and an improved product mix.

Sterling Du, Chairman and CEO of O2Micro commented, “We are pleased to announce our anticipated fourth quarter improvements in Revenue Guidance and Gross Margins which reflect continued product ramp up in our high growth drivers for the consumer and industrial end markets, including but not limited to the high end sector.  We believe our solutions for these markets will continue to contribute to our top-line growth and lead O₂Micro back to profitability.”

No conference call will be held in conjunction with this financial guidance update. Additional information will be available when the Company reports its fourth quarter results on January 25^th, 2017.

About O₂Micro

Founded in April 1995, O₂Micro develops and markets innovative power management components for the Computer, Consumer, Industrial, Automotive and Communications markets. Products include LED General Lighting, Backlighting, Battery Management, and Power Management.

O₂Micro International maintains offices worldwide. Additional company and product information can be found on the company website at www.o2micro.com.

O₂Micro, the O₂Micro logo, and combinations thereof are registered trademarks of O₂Micro. All other trademarks or registered trademarks are the property of their respective owners.

Statements made in this release that are not historical, including statements regarding O₂Micro’s or management’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. Factors that could cause actual results to differ materially include risks and uncertainties such as reduced demand for products of electronic equipment manufacturers which include O₂Micro’s products due to adverse economic conditions in general or specifically affecting O₂Micro’s markets, technical difficulties and delays in the developments process, and errors in the products. You are also referred to the Form F-1 in connection with the company’s initial public offering in August 2000, Form F-3 in connection with the company’s public offering in November 2001, and the annual reports on Form 20-F, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The company assumes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information:
Investor Relations, O2Micro
Phone: 408.987.5920, x8888
Email:  ir@o2micro.com

$EVOK Additional #Gimoti #Diabetic #Gastroparesis Data Quite Promising

Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity

Investor Contact:
The Ruth Group
Tram Bui
Tel: 646-536-7035
tbui@theruthgroup.com

$TISA #DonDixon Named Chairman of the Board of Directors

Izhak Nakar Steps Down from Position of Active Chairman and Remains Member of Board

TEL AVIV, Israel and PLANO, Texas, Jan. 03, 2017  — Top Image Systems, Ltd. (NASDAQ:TISA), a global innovator of intelligent content processing solutions, today announced that Mr. Don Dixon has assumed the position of Chairman of the Board of Directors for the Company effective January 1, 2017. Izhak Nakar, Company Founder and Active Chairman of the Board, decided to step down from his position as Active Chairman; Mr. Nakar will retain his membership on the Board and continues to hold a stake in the Company.

With Mr. Dixon agreeing to assume the position of Chairman of the Board and the Company now under the active management of an experienced and professional executive management team, including CEO Brendan Reidy appointed in August 2016 and the CTO, CSO, CFO, CMO and regional Presidents, Mr. Nakar has decided to step down from the position of Active Chairman in order to invest more of his time in managing the other companies in his portfolio and to devote more attention to personal pursuits.

Mr. Dixon, Managing Director of Trident Capital, a major shareholder in Top Image Systems, has extensive experience in transforming and growing shareholder value for the companies in his broad portfolio. He brings his expertise, experience and network to each of his portfolio companies and has helped many to become industry leaders, including Qualys, Merchant e-Solutions, Bytemobile, CSG Systems, and eGistics, Inc. which was acquired by TISA in 2014. Over the course of his career, Mr. Dixon has had successful exits from 36 companies, including serving on the Board of Affiliated Computer Systems which was later sold to Xerox.  Don is Co-Chairman of the Advisory Committee of the Princeton University School of Engineering and Applied Sciences and serves on the Advisory Board of the Harvard Kennedy School Center for Public Leadership.

“As a member of the Board of Directors of Top Image Systems, having also served on the Board of Directors of eGistics and having facilitated the acquisition of eGistics by the Company, I am looking forward to providing additional guidance to accelerate the Company’s transformational initiatives, improve its performance and deliver customer and shareholder value,” commented Don Dixon. “I have full faith and confidence in the leadership provided by the Company’s CEO Brendan Reidy and its executive management team to help us achieve the Company’s objectives. Brendan and I have worked together for over 15 years and he has served as CEO of three of our companies, served as an active Board member for other Trident companies and worked with us as a Venture Partner. Most recently, Brendan spearheaded the turnaround of XRS Corp. contributing to a twelve-fold increase in stock price and a highly successful acquisition by Vista Equity Partners.”

Mr. Nakar, who founded the Company and served as its Chairman and CEO and then returned to serve as Active Chairman in 2009, has led the Company in its development of technological innovations and in expanding the Company’s global reach. Upon Mr. Nakar’s return to Top Image Systems in 2009, the Company enjoyed a positive turnaround during which the TISA stock price and market cap increased significantly. He oversaw the Company’s acquisition of eGistics and subsequent strategic investments, investing some $10 million to transform the company by consolidating its product portfolio, moving towards a cloud-based SaaS business model and leveraging the Company’s process automation knowhow to build a suite of capture-driven process automation solutions, starting with enhanced Financial Process Automation (FPA) solutions via on-premise, cloud and mobile delivery models that will serve as a powerful growth engine for the Company in the years ahead.

“Mr. Nakar has made an enormous contribution to the Company as Active Chairman and as a major shareholder to drive revenue growth, profitability and to generate shareholder value for the Company during his tenure. I would like to take this opportunity to extend our deepest appreciation and gratitude for Izhak’s leadership and unwavering commitment to Top Image Systems,” said Don Dixon.

“It has been an honor and a privilege for me to serve as the Company’s Active Chairman,” said Izhak Nakar, Founder and Active Chairman, Top Image Systems. “I have the utmost confidence that the Company is on the right track and that under the leadership of Don Dixon as Chairman, Brendan Reidy as CEO, and with the support of the Board and executive management team, we will further strengthen our market reach and capitalize on our opportunities, increase revenues and profits and meet our commitments to the Company’s shareholders.”

About Top Image Systems

Top Image Systems™ (TIS™) Ltd. is a global innovator of on-premise and cloud-based applications that optimize content-driven business processes such as procure to pay operations, remittance processing, integrated receivables, customer response management and more.  Whether originating from mobile, electronic, paper or other sources, TIS solutions automatically capture, process and deliver content across enterprise applications, transforming information entering an organization into useful and accessible electronic data, delivering it directly and efficiently to the relevant business system or person for action with as little manual handling as possible.  TIS’ solutions are marketed in more than 40 countries through a multi-tier network of distributors, system integrators, value-added resellers and strategic partners. Visit the company’s website at http://www.TopImageSystems.com for more information.

Top Image Systems Caution Concerning Forward-Looking Statements

Certain matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results expressed or implied in those forward looking statements. Words such as “will,” “expects,” “anticipates,” “estimates,” and words and terms of similar substance in connection with any discussion of future operating or financial performance identify forward-looking statements. These statements are based on management’s current expectations or beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially including, but not limited to, risks in product development, approval and introduction plans and schedules, rapid technological change, customer acceptance of new products, the impact of competitive products and pricing, the lengthy sales cycle, proprietary rights of TIS and its competitors, risk of operations in Israel, government regulation, litigation, general economic conditions and other risk factors detailed in the Company’s most recent annual report on Form 20-F and other subsequent filings with the United States Securities and Exchange Commission. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

TIS Company Contact:
Shelli Zargary
Director of Corporate Marketing and Investor Relations
shelli.zargary@topimagesystems.com
+972 3 767 9114

TIS Investors Contact:
James Carbonara
Regional Vice President, Hayden IR
james@haydenir.com
+ 1 646 755 7412

$ZYNE Initiation of #FABC Exploratory #Phase2 #Clinical of #ZYN002 #CBD Gel

DEVON, Pa., Jan. 03, 2017 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated the FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) exploratory Phase 2 clinical trial of ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome. ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery.

Fragile X syndrome (FXS) is an autism spectrum disorder and the most common inherited intellectual disability in males and a significant cause of intellectual disability in females. It is caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide). The disorder negatively affects synaptic function, plasticity and neuronal connections and results in a spectrum of intellectual disabilities, social anxiety and memory problems.  In the US, there are about 71,000 patients suffering with FXS.

“Fragile X syndrome is devastating to patients and their caregivers and we are very hopeful that ZYN002 CBD gel can provide relief for this underserved patient group,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We anticipate having top line results for the FAB-C trial late in the first half of 2017.  With an orphan drug designation granted by the Food and Drug Administration for Fragile X syndrome, we look forward to working with the FDA to bring a treatment to patients as fast as possible.”

The FAB-C Trial is an exploratory clinical trial designed to evaluate the safety and efficacy of ZYN002 CBD gel in approximately 16 patients between the ages of 8-17 years with Fragile X syndrome. Dosing will be initiated at 50 mg of CBD in ZYN002 4.2% gel once daily and may be titrated up to 125 mg two times per day during the six-week titration period. Between weeks six to twelve, patients will receive a maintenance dose of 50 mg, 100 mg or 250 mg daily of CBD in ZYN002 4.2% gel.  The primary outcome measures include changes in anxiety, depression and mood as measured by the ADAMS scale, a validated patient reported outcomes questionnaire. Other measurements that will be observed include the Aberrant Behavior Checklist and visual analog scale (VAS) to assess for hyperactivity/impulsivity.

About ZYN002 CBD Gel
Zynerba’s ZYN002 CBD gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and is being studied in adult epilepsy patients with focal seizures, osteoarthritis and Fragile X syndrome.  ZYN002 is a clear, permeation-enhanced gel that is designed to provide consistent, controlled drug delivery transdermally with twice-daily dosing. Transdermal therapeutics are absorbed through the skin directly into the systemic circulation, avoiding first-pass liver metabolism and potentially enabling lower dosage levels of active pharmaceutical ingredients and rapid and reliable absorption with high bioavailability. In addition, transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of CBD into THC (associated with psychoactive effects), as demonstrated in a Zynerba-sponsored in vitro study.

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol (CBD), a non-psychoactive cannabinoid, and tetrahydrocannabinol (THC). Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. ZYN002, the Company’s CBD gel, is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel. In June 2016, the company initiated the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial of ZYN002 CBD gel in refractory epilepsy patients with focal seizures, the most common form of epilepsy in adults. In August 2016, the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial in patients with knee pain due to OA was initiated. In December 2016, the Company initiated the exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial in children with Fragile X syndrome (FXS). Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC. A Phase 1 clinical trial for ZYN001 is planned to begin in the first half of 2017. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. For example, there can be no guarantee that the Company will obtain approval for ZYN002 or ZYN001 from the U.S. Food and Drug Administration (FDA) or foreign regulatory authorities; even if ZYN002 or ZYN001 are approved, the Company may not be able to obtain the label claims that it is seeking from the FDA. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the success, cost and timing of the Company’s product development activities, studies and clinical trials; the success of competing products that are or become available; the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; and the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10K, quarterly reports on Form 10Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contacts
Jim Fickenscher, CFO and VP, Corporate Development
Zynerba Pharmaceuticals
484.581.7483
Fickenscherj@zynerba.com

Kimberly Minarovich
Argot Partners 
212.600.1902 
kimberly@argotpartners.com

Media Contact
Eliza Schleifstein 
Argot Partners 
973.361.1546 
eliza@argotpartners.com

$KOPN Enters Into #StrategicRelationship With #Goertek

Kopin Corporation (Nasdaq:KOPN), a leading developer of innovative wearable computing technologies and solutions, today announced it had entered into a strategic relationship with Goertek Inc. (“Goertek”), a leading innovative global technology company headquartered in Weifang China that provides vertically integrated total solutions and services to globally-renowned companies such as Samsung, Sony, Microsoft, Huawei and Xiaomi to name a few.

Under the terms of the stock sale agreement, Kopin will sell 7,339,000 shares of Kopin’s common stock to Goertek for US $23,851,750 ($3.25 per share). This represents approximately 9.8% of Kopin’s total outstanding shares of common stock. In addition Kopin and Goertek have entered into agreements to jointly develop and commercialize a range of technologies and wearable products. The goal of the partnership is to utilize Goertek’s industry-leading expertise in design and manufacturing to further develop and sell a range of wearable products incorporating Kopin technologies and components.

“Our partnership with Goertek will enable Kopin to leverage their world class capabilities to commercialize our innovative components and further improve our system products,” said Dr. John C.C. Fan, Kopin’s President and CEO. “In addition to our transmissive and reflective LCD products, we have developed our industry-leading Whisper^® Voice Chip and most recently announced our OLED Lightning^TM microdisplay with 2048 x 2048 resolution with unique Pantile™ Optics which we will demonstrate at CES 2017 this week. We will work with Goertek to incorporate our Whisper Voice Chip and Lightning display into the product designs Goertek provides to its customers. We will also work closely with Goertek to develop system products for consumer mobile augmented reality (AR) and virtual reality (VR) markets.”

“We are excited with this strategic relationship with Kopin which has innovative technologies and products,” said Long Jiang, Goertek’s CEO. “Goertek is the world’s leading designer and manufacturer of VR/AR and other wearable products. This partnership with Kopin will enable us to provide our customers and partners with cutting edge technologies and products for better performance and designs in the fast growing wearable market.”

The stock sale is subject to standard closing conditions and is scheduled for completion by January 27, 2017.

About Goertek

Goertek Inc. was established in June 2001, and listed on the Shenzhen Stock Exchange in May, 2008. As a leading innovative high-tech company, Goertek’s main focuses consist of R&D, production and sales of electro-acoustic components, optical components, and smart hardware system products. Goertek provides vertically integrated total solutions and services to globally-renowned consumer electronics companies. Goertek is one of the main high-end VR/AR ODM solutions providers in the world.

Since Goertek’s establishment in 2001, Goertek has high performance with a consistent and rapid growth rate. By the end of 2015 sales revenue had exceeded over 13.7 billion RMB (total assets 19.2 billion RMB). By market share, Goertek is a top ranked company in the miniature microphone. For more information, please visit Goertek’s website at www.goertek.com.

About Kopin

Kopin Corporation is a leading developer and provider of innovative wearable technologies and solutions for integration into head-worn computing and display systems to military, industrial and consumer customers. Kopin’s technology portfolio includes ultra-small displays, optics, speech enhancement technology, system and hands-free control software, low-power ASICs, and ergonomically designed smart headset reference systems. Kopin’s proprietary components and technology are protected by more than 300 global patents and patents pending. For more information, please visit Kopin’s website at www.kopin.com.

Kopin, Whisper, Lightning, Pantile, and Solos are trademarks of Kopin Corporation.

Forward-Looking Statements

Statements in this press release may be considered “forward-looking” statements under the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements relating to our statement that under the terms of the stock sale agreement the Company will sell 7,339,000 shares of the Company’s common stock for $23,851,750 ($3.25 per share); the Company and Goertek have entered into agreements to jointly develop and commercialize a range of technologies and wearable products; the goal of the partnership is to utilize Goertek’s industry leading expertise in design and manufacturing to further develop and sell wearable products incorporating the Company’s technologies and components; the Company’s partnership with Goertek will enable the Company to leverage Goertek’s world class capabilities to commercialize the Company’s innovative components and further improve the Company’s system products; the Company will work with Goertek to incorporate its Whisper Voice Chip and Lightning display into the product designs Goertek provides to its customers; the Company will also work closely with Goertek to develop system products for consumer mobile AR and VR markets; and the accelerating growth Goertek sees in the sale of wearable products. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: The sale of the stock to Goertek may not be completed; the Company and Goertek may not develop or commercialize any technology or products; the partnership may not develop and or sell wearable products based on the Company’s technologies and components; Goertek may not incorporate the Company’s components, Whisper Voice chip or Lightning Display in the product designs it provides to its partners and customers; the Company and Goertek may not develop system products for consumer mobile AR and VR markets; the wearable market may not grow fast; it may take longer than the Company estimates to develop products; the Company’s products may not be accepted by the market place; there may be issues that prevent the adoption or further development of the Company’s wearable computing technologies; manufacturing, marketing or other issues may prevent either the adoption or acceptance of products; the Company might be adversely affected by competitive products and pricing; new product initiatives and other research and development efforts may be unsuccessful; the Company could experience the loss of significant customers; costs to produce the Company’s products might increase significantly, or yields could decline; the Company’s customers might be unable to ramp production volumes of their products, manufacturing delays, technical issues, economic conditions or external factors may prevent the Company from achieving its goals; and other risk factors and cautionary statements listed in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the 12 months ended December 26, 2015, and the Company’s subsequent filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to the Company and only as of the date on which they are made. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances occurring after the date of this release.

$XBIO to Present at #BiotechShowcase 2017

Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that Scott Maguire, Xenetic’s Chief Executive Officer will present at the 9^th Annual Biotech Showcase™ Conference on Monday, January 9 at 3:00 p.m. PT in San Francisco, CA.

During his presentation, Mr. Maguire will provide a corporate update and discuss the Company’s clinical and regulatory progress for its in-house product candidates, as well as those being developed with Xenetic’s partners. Mr. Maguire will also discuss the Company’s up to $100 million license deal with Shire, one of the Company’s largest shareholders, along with the clinical status of the PSA-Recombinant SHP656 or Factor VIII being developed as a long-acting therapeutic for the treatment of hemophilia utilizing Xenetic’s proprietary PolyXen™ platform technology.

A live webcast of the presentation will be available by accessing the IR Calendar in the Investors section of Xenetic’s website (www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic’s proprietary drug development platforms include PolyXen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. Xenetic’s lead investigational product candidates include FDA orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease.

Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic’s PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is one of the Company’s largest shareholders having invested $10 million in the common stock of the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic’s PSA patented and proprietary technology in combination with Shire’s proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales.

Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company’s website at www.xeneticbio.com and connect on Twitter, LinkedIn, Facebook and Google+.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding expected benefits of NGS cancer panels, the ability to accurately determine the heritable factors increasing the risk of cancer, permitting tailored treatment, screening and prevention of cancer in patients, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Jenene Thomas Communications, LLC.
Jenene Thomas, 908-938-1475
jenene@jenenethomascommunications.com

$CBAY Exclusive #Licensing Agreement w/ #KowaPharmaceuticals America for #Arhalofenate

— Kowa to fully fund development through NDA approval
— CymaBay to receive up to $205M in up-front and milestone payments
— Conference call and webcast today at 4:30 pm ET

NEWARK, Calif., Jan. 03, 2017  — CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it has entered into an exclusive license agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States (U.S.).

Under the terms of the agreement, CymaBay will receive up to $15 million in upfront and near-term milestone payments and is eligible to receive up to an additional $190 million in payments based upon the achievement of specific development, regulatory and sales milestones.  CymaBay is also eligible to receive tiered, double digit royalties on future sales of arhalofenate products.  Kowa will be responsible for all development and commercialization costs. CymaBay had earlier reached agreement with the Food and Drug Administration (FDA) on the size and scope of the Phase 3 program which is estimated to cost $100 million. CymaBay retains full development and commercialization rights for the rest of the world.  Locust Walk served as a transaction advisor to CymaBay.

Kowa Pharmaceuticals America, Inc., a US subsidiary of Kowa Company, Ltd., a privately held, multinational company based in Japan, markets cardiometabolic drugs including LIVALO® (pitavastatin) and Lipofen® (fenofibrate capsules, USP) in the U.S. The company focuses its efforts on the successful commercialization of its current and near term portfolio of pharmaceutical products with an established and growing primary care sales force in the U.S.

“We are extremely pleased to enter into this agreement with Kowa to develop and market arhalofenate in the U.S. Kowa has proven development capabilities as well as the resources to carry out a large Phase 3 development program. They also have an established primary care sales force to market arhalofenate products. As arhalofenate is a potential novel therapy for gout, a disease most often treated by primary care physicians, it is a very good fit with Kowa’s established strength in this area,” said Harold Van Wart, Ph.D., President and CEO of CymaBay. “Identifying a partner to complete the Phase 3 development and commercialization of arhalofenate has been a key part of CymaBay’s strategy. It enables us to advance arhalofenate to the market while allowing us to focus our internal resources on the rest of our pipeline which addresses serious and rare disorders.”

Arhalofenate is an oral, once-daily dual-acting drug candidate for the treatment of gout.   In an extensive Phase 2 clinical program in patients with gout, arhalofenate has been shown to decrease serum uric acid while also suppressing gout flares. It is the first compound in a new class of gout therapy that CymaBay refers to as Urate Lowering Anti-Flare Therapy (ULAFT). Arhalofenate is being developed as a combination product with febuxostat. CymaBay has completed end-of-Phase 2 discussions with the FDA and has come to agreement on a Phase 3 program that would provide a very competitive label that can capture the unique dual actions of arhalofenate.

Conference Call and Webcast

CymaBay management will host a conference call and webcast today, January 3, 2017 at 4:30 p.m. ET to discuss this licensing agreement and provide a corporate update on the company’s strategy. To access the live conference call, please dial (877) 407-0784 from the U.S. and Canada, or (201) 689-8560 internationally. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http://ir.cymabay.com/events. A replay of the webcast will be available on the Company’s website for 14 days following the live event.

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of seladelpar in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications.  Previously, a Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile.  Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed to Kowa Pharmaceuticals America, Inc. in the U.S. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

About Arhalofenate

Arhalofenate is an oral, once-daily dual-acting drug candidate for the treatment of gout that both lowers serum uric acid (sUA) and suppresses flares. It is the first compound in a new class of gout therapy that CymaBay refers to as Urate Lowering Anti-Flare Therapy (ULAFT).  Arhalofenate increases the excretion of uric acid into urine resulting in a decrease in sUA levels.  This is accomplished by its inhibition of the urate transporter URAT1 in the proximal tubules of the kidney.  Arhalofenate produces its uricosuric effect gradually and appears to have a favorable overall and renal safety profile in studies completed to date in over 1,100 patients. In a Phase 2 study of arhalofenate in combination with the xanthine oxidase inhibitor febuxostat, which works by blocking the production of uric acid, the sUA lowering activity of arhalofenate was complementary and additive to that of febuxostat.  The anti-flare activity of arhalofenate is attributable to its suppression of the urate crystal-induced production of IL-1β in gouty joints.  The goal of the Phase 3 program is to study the combination of arhalofenate and febuxostat to confirm the urate lowering and anti-flare activity.

Current treatment guidelines for gout recommend the use of urate lowering therapies (ULTs) to reverse hyperuricemia in order to remove deposits of pro-inflammatory urate crystals. The minimal goal of this treatment is to reduce sUA levels to below 6 mg/dL.  The goal for patients with a more advanced form of the disease called tophaceous gout is <5 mg/dL. Many patients treated with currently marketed xanthine oxidase inhibitors (allopurinol or febuxostat) alone do not reach these goals.  In previously published studies, arhalofenate in combination with febuxostat has been shown to significantly increase the number of patients achieving their sUA goals. Paradoxically, the initiation of ULT triggers an increased risk of gout flares for the first six months or more. The anti-inflammatory activity of arhalofenate has been shown in clinical studies to suppress flares, making it uniquely suited for the treatment of gout.

Cautionary Statements

The statements in this press release regarding the potential future performance of CymaBay’s product candidates are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of CymaBay’s product candidates, including but not limited to the expected Phase 3 trial of Arhalofenate and the anticipated resulting label, could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay’s product development activities, including clinical trials of seladelpar and arhalofenate; effects observed in trials to date which may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay’s product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay’s filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Contacts

Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
sshah@cymabay.com

or

Hans Vitzthum
LifeSci Advisors, LLC
(212) 915-2568
Hans@LifeSciAdvisors.com

$IDXG Agreement with #BCBS to Support Enhanced Coverage

PARSIPPANY, N.J., Jan. 3, 2017  — Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that the Company has entered in to an Agreement with the Blue Cross Blue Shield (BCBS) Association’s Center for Clinical Effectiveness “Evidence Street”, a program that, while not making coverage decisions, provides the Company with the opportunity to provide available evidence for its molecular Thyroid and Pancreas tests, to support further coverage determinations among Blue Cross Blue Shield and other health plans. Blue Cross Blue Shield’s 36 independent plans and Companies account for approximately 106 million covered lives in the U.S.

As part of the Agreement, Interpace will work with Evidence Street to develop the optimal ways for the Company to secure and preserve ongoing coverage for not only its currently marketed products but also for those tests in the pipeline being launched in the near future. All of Interpace’s currently marketed products are covered regionally by Medicare and numerous commercial plans, including certain BCBS plans.

While the BCBS plans apply numerous criteria in their evaluation of technologies, the two criteria most heavily weighted are clinical utility and patient outcomes.  The Company has conducted numerous studies for their products in both its Endocrine (Endo) franchise, i.e. ThyGenX® and ThyraMir®, and Gastrointestinal (GI) franchise including PancraGen® and BarreGen® for pancreatic and esophageal cancer respectively.  The data from these studies have been published in multiple peer-reviewed publications such as Journal of Clinical Endocrinology and Metabolism, American Journal of Gastroenterology, and Endoscopy.   These publications provide favorable conclusions regarding the clinical utility of the Company’s molecular tests.  The ECRI Institute, another independent review organization, published a review of PancraGen in April 2016, in which it concluded “PancraGen is more predictive of real life patient management than current guidelines.”

Jack E. Stover, President and CEO of Interpace Diagnostics stated, “We are excited about our evolving relationship with Blue Cross and Blue Shield’s Evidence Street which, we believe, will help ensure that we continue to develop and provide the information and data necessary to support and secure broader based insurance coverage and reimbursement for all of our products.  This relationship is another important milestone in our reimbursement strategy and, when added to our recent AETNA insurance approval for ThyraMIR  and New York State approval to market ThyGenX, bodes well for our commercial prospects in 2017 and beyond.”

About Thyroid Nodules, ThyGenX and ThyraMIR testing

According to the American Thyroid Association, approximately 15% to 30% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.  The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier.  MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs.  Both ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

About Pancreatic Cysts and PancraGEN

PancraGEN is a pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN is 90% accurate, according to clinical studies, enabling effective risk stratification of patients.  Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.

About Interpace Diagnostics Group, Inc.

Interpace Diagnostics is a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, our ability to restructure our debt and other obligations, our ability to meet our obligations as they become due,, the market’s acceptance of our molecular diagnostic tests; our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 30, 2016 as amended on April 29, 2016 and June 14, 2016, and the Quarterly Report on Form 10-Q filed with the SEC on November 17, 2016. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:
Interpace Diagnostics Group, Inc.
Investor Relations:
Paul Kuntz – Redchip
paul@redchip.com